Australia's Firebrick Pharma hits record low on unfavourable nasal spray trial results

Firebrick Pharma

13/09/2023 02:22

** Shares of Firebrick Pharma Ltd  FRE.AX  fall as much as
77.9% to an all-time low of A$0.073
    ** Co stock sees its biggest intraday pct drop   
    ** The pharmaceutical co provides efficacy analysis results
of co's Phase 3 trial of Nasodine® nasal spray 
    ** Says analysis shows that the trial did not meet its
primary endpoint
    ** About 10.6 mln shares change hands, compared with 30-day
average trading volume of 131,770 shares 
    ** Firebrick shares up 43.5% YTD, as of last close 
   

 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))